SG11201406888QA - Lysin-glutamic acid dipeptide derivatives - Google Patents
Lysin-glutamic acid dipeptide derivativesInfo
- Publication number
- SG11201406888QA SG11201406888QA SG11201406888QA SG11201406888QA SG11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA SG 11201406888Q A SG11201406888Q A SG 11201406888QA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- peptide
- basel
- designated states
- glutamic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
- B01J19/00—Chemical, physical or physico-chemical processes in general; Their relevant apparatus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
- C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/06—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members
- C07C2603/10—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings
- C07C2603/12—Ortho- or ortho- and peri-condensed systems containing three rings containing at least one ring with less than six ring members containing five-membered rings only one five-membered ring
- C07C2603/18—Fluorenes; Hydrogenated fluorenes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 21 November 2013 (21.11.2013) WIPOIPCT (10) International Publication Number WO 2013/171135 A1 (51) International Patent Classification: B01J19/00 (2006.01) C07C 271/34 (2006.01) (21) International Application Number: (22) International Filing Date: (25) Filing Language: (26) Publication Language: PCT/EP2013/059759 13 May 2013 (13.05.2013) English English (30) Priority Data: 12168119.1 15 May 2012 (15.05.2012) EP (71) Applicant (for all designated States except US): F. HOFF MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH). (71) Applicant (for US only): HOFFMANN-LA ROCHE INC. [US/US]; 340 Kingsland Street, Nutley, NJ 07110 (US). (72) Inventor: PUENTENER, Kurt; Gellertstrasse 135, CH- 4052 Basel (CH). (74) Agent: RAUBER, Beat; Grenzacherstrasse 124, CH-4070 Basel (CH). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: — of inventorship (Rule 4.17(ivf) Published: — with international search report (Art. 21(3)) (54) Title: LY SIN-GLUTAMIC ACID DIPEPTIDE DERIVATIVES R V>0 (I) i-H (57) Abstract: The invention relates to compounds of the formula (I) to a process for making same and to the use of the products in ® the solid phase peptide synthesis. The compounds of formula I are versatile peptide intermediates for the solid phase peptide syn - CJ thesis (SPPS) of peptide drugs which comprise Glu-fatty a alkyl side chain building block attached to a Lys-part of the peptide Q chain.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12168119.1A EP2664374A1 (en) | 2012-05-15 | 2012-05-15 | Lysin-glutamic acid dipeptide derivatives |
| PCT/EP2013/059759 WO2013171135A1 (en) | 2012-05-15 | 2013-05-13 | Lysin-glutamic acid dipeptide derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201406888QA true SG11201406888QA (en) | 2015-01-29 |
Family
ID=48430764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201406888QA SG11201406888QA (en) | 2012-05-15 | 2013-05-13 | Lysin-glutamic acid dipeptide derivatives |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US9522874B2 (en) |
| EP (3) | EP2664374A1 (en) |
| JP (1) | JP6162795B2 (en) |
| KR (2) | KR102094928B1 (en) |
| CN (1) | CN104271227B (en) |
| AR (1) | AR091044A1 (en) |
| AU (1) | AU2013261894B2 (en) |
| BR (1) | BR112014028334B1 (en) |
| CA (2) | CA3096624C (en) |
| ES (2) | ES2637415T3 (en) |
| HK (1) | HK1200753A1 (en) |
| HR (2) | HRP20171058T1 (en) |
| IL (1) | IL235425B (en) |
| MX (2) | MX363728B (en) |
| MY (2) | MY184184A (en) |
| NZ (1) | NZ631215A (en) |
| PL (2) | PL3127604T3 (en) |
| RU (1) | RU2640812C2 (en) |
| SG (1) | SG11201406888QA (en) |
| SI (2) | SI2849882T1 (en) |
| WO (1) | WO2013171135A1 (en) |
| ZA (1) | ZA201407528B (en) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (en) | 2012-10-09 | 2018-02-26 | Санофі | Exendin-4 derivatives as dual glp1/glucagon agonists |
| AU2013366691A1 (en) | 2012-12-21 | 2015-07-09 | Sanofi | Exendin-4 derivatives |
| GB201315335D0 (en) * | 2013-08-29 | 2013-10-09 | Of Singapore | Amino diacids containing peptide modifiers |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| TW201609799A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/GIP receptor agonists |
| TW201609797A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists |
| TW201609796A (en) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | Non-acylated EXENDIN-4 peptide analogues |
| TW201625668A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists |
| TW201625670A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Dual GLP-1/glucagon receptor agonists derived from EXENDIN-4 |
| TW201625669A (en) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | Peptidic dual GLP-1/glucagon receptor agonists derived from Exendin-4 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (en) | 2015-06-05 | 2017-09-27 | Sanofi Sa | PROPHARMS THAT INCLUDE A DUAL AGONIST GLU-1 / GLUCAGON CONJUGATE HIALURONIC ACID CONNECTOR |
| TW201706291A (en) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | New EXENDIN-4 derivatives as selective peptidic dual GLP-1/glucagon receptor agonists |
| CA3018618A1 (en) | 2016-03-23 | 2017-09-28 | Bachem Holding Ag | Method for preparing glucagon-like peptides |
| WO2020208409A1 (en) * | 2019-04-10 | 2020-10-15 | Dr. Reddy’S Laboratories Limited | Improved processes for the preparation of peptide intermediates/modifiers |
| CN111454180A (en) * | 2020-04-10 | 2020-07-28 | 大连阿拉宁生物技术有限公司 | Somalutide side chain intermediate and preparation method thereof |
| CN113004370B (en) * | 2021-02-09 | 2022-06-17 | 宁波绿之健药业有限公司 | Dipeptide capable of relieving hyperuricemia and regulating intestinal flora and application thereof |
| EP4345104A1 (en) | 2022-09-30 | 2024-04-03 | Bachem Holding AG | Method for preparing liraglutide |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69737479T4 (en) * | 1996-08-30 | 2010-05-06 | Novo Nordisk A/S | GLP-1 DERIVATIVES |
| EP1634605A3 (en) * | 2000-03-08 | 2006-10-11 | Novo Nordisk A/S | treatment of dyslipidemia in a patient having type 2 diabetes |
| US20060258580A1 (en) * | 2003-05-14 | 2006-11-16 | Regents Of The University Of Michigan | Modulators of Nod1 signaling |
| JP2006233405A (en) * | 2005-08-16 | 2006-09-07 | Asahi Kasei Chemicals Corp | Fiber treatment agent |
| IE20060841A1 (en) * | 2006-11-21 | 2008-05-28 | Ipsen Mfg Ireland Ltd | Boc and fmoc solid phase peptide synthesis |
| JP2008290987A (en) * | 2007-05-28 | 2008-12-04 | Shiseido Co Ltd | Cmc-restoring agent, hair cosmetic, and method for restoring cmc |
| JP5127316B2 (en) * | 2007-06-22 | 2013-01-23 | 旭化成ケミカルズ株式会社 | Chemical mechanical polishing composition |
| UA104605C2 (en) * | 2008-12-15 | 2014-02-25 | Зіленд Фарма А/С | Glucagon analogues |
| DK2454282T3 (en) * | 2009-07-13 | 2015-05-04 | Zealand Pharma As | acetylated glucagonanaloger |
| JP2011057663A (en) * | 2009-08-11 | 2011-03-24 | Sumitomo Chemical Co Ltd | Compound and photoresist composition |
| CN102286092B (en) * | 2011-09-14 | 2014-01-01 | 深圳翰宇药业股份有限公司 | Solid-phase synthesis method of liraglutide |
| PE20142113A1 (en) | 2011-12-23 | 2014-12-03 | Zealand Pharma As | GLUCAGON ANALOGS |
-
2012
- 2012-05-15 EP EP12168119.1A patent/EP2664374A1/en not_active Ceased
-
2013
- 2013-05-13 SG SG11201406888QA patent/SG11201406888QA/en unknown
- 2013-05-13 JP JP2015512007A patent/JP6162795B2/en active Active
- 2013-05-13 SI SI201330739T patent/SI2849882T1/en unknown
- 2013-05-13 RU RU2014148530A patent/RU2640812C2/en active
- 2013-05-13 PL PL16179885T patent/PL3127604T3/en unknown
- 2013-05-13 SI SI201331208T patent/SI3127604T1/en unknown
- 2013-05-13 BR BR112014028334-6A patent/BR112014028334B1/en active IP Right Grant
- 2013-05-13 MX MX2017006522A patent/MX363728B/en unknown
- 2013-05-13 MY MYPI2018000443A patent/MY184184A/en unknown
- 2013-05-13 KR KR1020197014335A patent/KR102094928B1/en active IP Right Grant
- 2013-05-13 AU AU2013261894A patent/AU2013261894B2/en active Active
- 2013-05-13 PL PL13722408T patent/PL2849882T3/en unknown
- 2013-05-13 CN CN201380024470.5A patent/CN104271227B/en active Active
- 2013-05-13 EP EP16179885.5A patent/EP3127604B1/en active Active
- 2013-05-13 KR KR1020147031824A patent/KR102018160B1/en active IP Right Grant
- 2013-05-13 CA CA3096624A patent/CA3096624C/en active Active
- 2013-05-13 NZ NZ631215A patent/NZ631215A/en unknown
- 2013-05-13 WO PCT/EP2013/059759 patent/WO2013171135A1/en active Application Filing
- 2013-05-13 MY MYPI2014703386A patent/MY172395A/en unknown
- 2013-05-13 EP EP13722408.5A patent/EP2849882B1/en active Active
- 2013-05-13 ES ES13722408.5T patent/ES2637415T3/en active Active
- 2013-05-13 ES ES16179885.5T patent/ES2692364T3/en active Active
- 2013-05-13 MX MX2014013505A patent/MX349822B/en active IP Right Grant
- 2013-05-13 CA CA2868144A patent/CA2868144C/en active Active
- 2013-05-14 AR ARP130101662A patent/AR091044A1/en active IP Right Grant
-
2014
- 2014-10-16 ZA ZA2014/07528A patent/ZA201407528B/en unknown
- 2014-10-30 IL IL235425A patent/IL235425B/en active IP Right Grant
- 2014-11-12 US US14/539,126 patent/US9522874B2/en active Active
-
2015
- 2015-02-05 HK HK15101247.2A patent/HK1200753A1/en unknown
-
2016
- 2016-11-10 US US15/348,093 patent/US9802886B2/en active Active
-
2017
- 2017-07-11 HR HRP20171058TT patent/HRP20171058T1/en unknown
- 2017-10-11 US US15/730,585 patent/US20180029978A1/en not_active Abandoned
-
2018
- 2018-10-17 HR HRP20181696TT patent/HRP20181696T1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201406888QA (en) | Lysin-glutamic acid dipeptide derivatives | |
| SG11201407534PA (en) | New diazaspirocycloalkane and azaspirocycloalkane | |
| SG11201408539UA (en) | Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof | |
| SG11201804170RA (en) | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders | |
| SG11201903908PA (en) | Novel substituted n-(3-fluoropropyl)-pyrrolidine compounds, processes for their preparation and therapeutic uses thereof | |
| SG11201807426WA (en) | Immunomodulators | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201408094YA (en) | Neprilysin inhibitors | |
| SG11201908640TA (en) | Pyrrolidinones and a process to prepare them | |
| SG11201407228PA (en) | N-aryltriazole compounds as lpar antagonists | |
| SG11201403402VA (en) | Compounds | |
| SG11201500005SA (en) | Pyrimidine pyrazolyl derivatives | |
| SG11201408224SA (en) | Novel ruthenium complexes, their use in the metathesis reactions, and a process for carrying out the metathesis reaction | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201407220YA (en) | N-alkyltriazole compounds as lpar antagonists | |
| SG11201805387RA (en) | Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201407575PA (en) | 5-amino[1,4]thiazines as bace 1 inhibitors | |
| SG11201406945QA (en) | Process for the preparation of 2-deoxy-2-fluoro-2-methyl-d-ribofuranosyl nucleoside compounds | |
| SG11201908325PA (en) | Process for the preparation of glucuronide drug-linkers and intermediates thereof | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201900904PA (en) | Methods for cross coupling | |
| SG11201407988UA (en) | Process for improved opioid synthesis | |
| SG11201408037SA (en) | Humanized anti-trka antibodies with amino acid substitutions |